STOCK TITAN

AVITA Medical issues 119,375 shares to Perceptive

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

AVITA Medical, Inc. (RCEL) reported that Perceptive Credit Holdings V, LP and OrbiMed Royalty & Credit Opportunities IV, LP and OrbiMed Royalty & Credit Opportunities IV Offshore, LP exercised previously disclosed warrants on November 11, 2026 through cashless exercises. AVITA withheld 30,625 shares covered by Perceptive’s warrant in respect of the exercise price and issued 119,375 shares to Perceptive; it withheld 261,503 shares covered by OrbiMed’s warrant and issued 148,158 shares to the two OrbiMed partnerships.

Perceptive’s warrant was exercisable for up to 150,000 shares in the event AVITA borrowed additional funds under their Credit Agreement. AVITA borrowed those funds on November 3, 2026. The OrbiMed warrant was exercisable for up to 409,661 shares.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Perceptive Warrant maximum Up to 150,000 shares Warrant exercisable upon AVITA borrowing additional funds under the Credit Agreement
Shares withheld for Perceptive exercise price 30,625 shares Cashless exercise on November 11, 2026
Shares issued to Perceptive 119,375 shares Cashless exercise on November 11, 2026
OrbiMed Warrant maximum Up to 409,661 shares Warrant exercisable for shares of AVITA common stock
Shares withheld for OrbiMed exercise price 261,503 shares Cashless exercise on November 11, 2026
Shares issued to OrbiMed 148,158 shares Cashless exercise on November 11, 2026
cashless exercise technical
"via a cashless exercise"
A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.
Credit Agreement financial
"under the Credit Agreement"
A credit agreement is a written loan contract between a borrower and a bank or other lender that lays out how much money can be borrowed, the interest rate, repayment schedule, fees, and the rules the borrower must follow. For investors, it matters because those terms affect a company’s cash costs, borrowing flexibility and risk of default — similar to how a mortgage’s rules determine a homeowner’s monthly budget and freedom to make changes.
exercise price financial
"in respect of the exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
ASX listing rules regulatory
"pursuant to ASX listing rules"
A set of regulatory requirements that companies must follow to be listed and remain listed on the Australian Securities Exchange (ASX), covering disclosure of important information, financial reporting, corporate governance, trading rules and conduct of directors. Investors rely on these rules because they act like a rulebook for a sports league—ensuring fair play, timely disclosure of material news and basic financial standards so shareholders can judge risk, value and trust the market.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did AVITA Medical (RCEL) issue in the Perceptive and OrbiMed warrant exercises?

AVITA issued 119,375 shares to Perceptive Credit Holdings V, LP and 148,158 shares to OrbiMed Royalty & Credit Opportunities IV, LP and OrbiMed Royalty & Credit Opportunities IV Offshore, LP on November 11, 2026. AVITA withheld 30,625 and 261,503 shares, respectively, in respect of the exercise prices.

What triggered the Perceptive warrant exercise at AVITA Medical (RCEL)?

The Perceptive Warrant was exercisable for up to 150,000 shares in the event AVITA borrowed additional funds under the Credit Agreement. AVITA borrowed those funds on November 3, 2026, and Perceptive exercised on November 11, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001762303false00017623032026-11-132026-11-13

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2026

 

 

AVITA Medical, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39059

85-1021707

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

28159 Avenue Stanford

Suite 220

 

Valencia, California

 

91355

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 661 367-9170

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

RCEL

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


Item 7.01 Regulation FD Disclosure.

On November 13 2026, AVITA Medical, Inc. (the “Company”) lodged certain filings on the Australian Securities Exchange (the “ASX”) disclosing the following two exercises of previously disclosed warrants:

 

Perceptive Credit Holdings V, LP (“Perceptive”) exercised the warrant certificate issued by the Company to Perceptive on June 5, 2026 (the “Perceptive Warrant”). As previously reported, the Perceptive Warrant was issued pursuant to that certain Credit Agreement and Guaranty, dated January 13, 2026, by and between Perceptive and the Company (the “Credit Agreement”) and was exercisable for up to 150,000 shares of Company common stock in the event that the Company borrowed additional funds under the Credit Agreement. The Company borrowed these funds on November 3, 2026. Perceptive exercised the Perceptive Warrant via a cashless exercise whereby the Company withheld 30,625 shares covered by the Perceptive Warrant in respect of the exercise price and issued the remaining 119,375 shares to Perceptive on November 11, 2026.

 

OrbiMed Royalty & Credit Opportunities IV, LP and OrbiMed Royalty & Credit Opportunities IV Offshore, LP (collectively, “OrbiMed”) exercised the warrant certificate issued by the Company to OrbiMed on October 18, 2023 (the “OrbiMed Warrant”). As previously reported, the OrbiMed Warrant was issued pursuant to that certain Credit Agreement, dated October 18, 2023, by and between an OrbiMed affiliate and the Company and was exercisable for up to 409,661 shares of Company common stock. OrbiMed exercised the OrbiMed Warrant via a cashless exercise whereby the Company withheld 261,503 shares covered by the OrbiMed Warrant in respect of the exercise price and issued the remaining 148,158 shares to OrbiMed on November 11, 2026.

 

 

The filings were lodged on the ASX pursuant to ASX listing rules.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

AVITA Medical, Inc.

 

 

 

 

Date:

November [13], 2026

By:

/s/ David O'Toole

 

 

 

Name: David O'Toole
Title: Chief Financial Officer

 


Filing Exhibits & Attachments

1 document

Keep reading